Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism

被引:82
作者
Nemeth, EF [1 ]
Fox, J [1 ]
机构
[1] NPS Pharmaceut Inc, Salt Lake City, UT 84108 USA
关键词
D O I
10.1016/S1043-2760(98)00119-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Ca2+ receptor is the primary mechanism regulating the secretion of parathyroid hormone (PTH). Ligands that activate this receptor (calimimetics) represent a novel means of lowering plasma levels of PTH. Two mechanistically distinct classes of calcimimetics that inhibit PTH secretion have been identified: type I calcimimetics are full agonists of the Ca2+ receptor and include Ca2+ and other polyvalent inorganic and organic cations; whereas type II calcimimetics, typified by phenylalkylamine compounds, behave like positive allosteric activators and increase, in a stereoselective manner the sensitivity of the Ca2+ receptor to activation by extracellular Ca2+. The phenylalkylamine calcimimetics are orally active and decrease the plasma levels of PTH and Ca2+ in patients with primary hyperparathyroidism (HPT), a disease that so far has resisted pharmacological intervention. Such compounds are similarly safe and effective in reducing PTH levels and preventing parathyroid cell hyperplasia in rats with HPT secondary to chronic renal insufficiency and they lower plasma levels of PTH in dialysis patients with secondary HPT. Calcimimetic compounds may provide a novel therapy for treating both primary and secondary HPT.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 35 条
[1]   A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure -: Rapid communication [J].
Antonsen, JE ;
Sherrard, DJ ;
Andress, DL .
KIDNEY INTERNATIONAL, 1998, 53 (01) :223-227
[2]  
Arnold Andrew, 1994, P407
[3]  
Bilezikian John P., 1994, P567
[4]   CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].
BROWN, EM ;
GAMBA, G ;
RICCARDI, D ;
LOMBARDI, M ;
BUTTERS, R ;
KIFOR, O ;
SUN, A ;
HEDIGER, MA ;
LYTTON, J ;
HEBERT, SC .
NATURE, 1993, 366 (6455) :575-580
[5]   Mutations in the calcium-sensing receptor and their clinical implications [J].
Brown, EM .
HORMONE RESEARCH, 1997, 48 (05) :199-208
[6]   Calcium-receptor-regulated parathyroid and renal function [J].
Brown, EM ;
Hebert, SC .
BONE, 1997, 20 (04) :303-309
[7]  
Coburn Jack W., 1994, P721
[8]   Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent [J].
Collins, MT ;
Skarulis, MC ;
Bilezikian, JP ;
Silverberg, SJ ;
Spiegel, AM ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04) :1083-1088
[9]   Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence [J].
Cosman, F ;
Lindsay, R .
CALCIFIED TISSUE INTERNATIONAL, 1998, 62 (06) :475-480
[10]   ANABOLIC ACTIONS OF PARATHYROID-HORMONE ON BONE [J].
DEMPSTER, DW ;
COSMAN, F ;
PARISIEN, M ;
SHEN, V ;
LINDSAY, R .
ENDOCRINE REVIEWS, 1993, 14 (06) :690-709